Precision Immunotherapy™
Clinical Trials

Email Alerts

Email Address *
Mailing Lists *

Enter the code shown above.

Abili-T Clinical Study for Secondary Progressive Multiple Sclerosis Overview

A phase 2 double blind, placebo controlled multi-center study to evaluate the efficacy and safety of Tcelna in subjects with Secondary Progressive multiple sclerosis.

  • Study conducted in the United States and Canada
  • 18-60 years of age with a diagnosis of Secondary Progressive multiple sclerosis
  • 5 subcutaneous injections annually
  • 2 year treatment period
  • 180 subjects (90 Tcelna: 90 placebo)

For more information on the Abili-T trial clinical trial, including participating sites, click here or go to and search NCT01684761 or by Abili-T.

Clinical Trials Sites

Site Site Name PI Name Contact Address 1 Contact Address 2 Contact City Contact State Contact Zip Code Phone Number